<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Measurements of <z:chebi fb="2" ids="8069">luminal</z:chebi> pH in the <z:mpath ids='MPATH_458'>normal</z:mpath> gastrointestinal tract have shown a progressive increase in pH from the duodenum to the terminal ileum, a decrease in the caecum, and then a slow rise along the colon to the rectum </plain></SENT>
<SENT sid="1" pm="."><plain>Some data in patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> suggest a substantial reduction below <z:mpath ids='MPATH_458'>normal</z:mpath> values in the right colon, while limited results in <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> have been contradictory </plain></SENT>
<SENT sid="2" pm="."><plain>Determinants of <z:chebi fb="2" ids="8069">luminal</z:chebi> pH in the colon include mucosal bicarbonate and <z:chebi fb="4" ids="24996">lactate</z:chebi> production, <z:mp ids='MP_0001794'>bacterial</z:mp> fermentation of carbohydrates and mucosal absorption of <z:chebi fb="0" ids="26666">short chain fatty acids</z:chebi>, and possibly intestinal transit </plain></SENT>
<SENT sid="3" pm="."><plain>Alterations in these factors, as a result of <z:e sem="disease" ids="C0151785" disease_type="Disease or Syndrome" abbrv="">mucosal disease</z:e> and changes in diet, are likely to explain abnormal pH measurements in <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) </plain></SENT>
<SENT sid="4" pm="."><plain>It is conceivable that reduced intracolonic pH in active <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> impairs bioavailability of <z:chebi fb="0" ids="6775">5-aminosalicylic acid</z:chebi> from pH dependent release formulations (<z:chebi fb="0" ids="6775">Asacol</z:chebi>, <z:chebi fb="0" ids="6775">Salofalk</z:chebi>) and those requiring cleavage by <z:mp ids='MP_0001794'>bacterial</z:mp> <z:chebi fb="3" ids="30106">azo</z:chebi> reductase (sulphasalazine, olsalazine, balsalazide), but further pharmacokinetic studies are needed to confirm this possibility </plain></SENT>
<SENT sid="5" pm="."><plain>Reports that balsalazide and olsalazine may be more efficacious in active and quiescent <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>, respectively, than <z:chebi fb="0" ids="6775">Asacol</z:chebi> suggest that low pH may be a more critical factor in patients taking directly pH dependent release than <z:chebi fb="3" ids="30106">azo</z:chebi> bonded preparations </plain></SENT>
<SENT sid="6" pm="."><plain>Reduced intracolonic pH also needs to be considered in the development of pH dependent colonic release formulations of <z:chebi fb="0" ids="3207">budesonide</z:chebi> and <z:chebi fb="2" ids="2948">azathioprine</z:chebi> for use in ulcerative and Crohn's <z:hpo ids='HP_0002583'>colitis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>This paper reviews methods for measuring gut pH, its changes in IBD, and how these may influence current and future therapies </plain></SENT>
</text></document>